Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference32 articles.
1. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J. Clin. Oncol.,2000
2. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vindesine alone in advanced non-small cell lung cancer;Le Chevalier;J. Clin. Oncol.,1994
3. Gemcitabine;Sandler;The Oncologist,1999
4. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin;Bonomi;J. Clin. Oncol.,2000
5. Phase II study of docetaxel (Taxotere) for advanced or metastatic platinum-refractory non-small cell lung cancer;Fossella;J. Clin. Oncol.,1995
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A feasibility study of bevacizumab and vinorelbine in patients with previously treated advanced non-squamous non-small-cell lung cancer;Molecular and Clinical Oncology;2017-03-08
2. Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small- cell lung cancer: a retrospective study;Lung Cancer: Targets and Therapy;2015-09
3. Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer;Chemotherapy;2015-04-28
4. A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe–Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019);European Journal of Cancer;2011-07
5. Biweekly Vinorelbine and Gemcitabine as Second-Line Treatment and Beyond in Non-Small Cell Lung Cancer;Chemotherapy;2010
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3